Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Adalimumab
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Adalimumab 40mg/0.4ml inj pre-filled disposable devices
1001030S0AAADAD
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | 4 |
|
Humira 40mg/0.4ml solution for injection pre-filled pens
1001030S0BBADAD
|
Humira | Adalimumab | Musculoskeletal and Joint Diseases | 4 |
|
Adalimumab 40mg/0.8ml inj pre-filled disposable devices
1001030S0AAABAB
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | 2 |
|
Adalimumab 40mg/0.4ml inj pre-filled syringes
1001030S0AAAEAE
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | 1 |
|
Amgevita HCF 40mg/0.4ml inj pre-filled pens
1001030S0BCAFAD
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | 1 |
|
Humira 20mg/0.2ml solution for injection pre-filled syringes
1001030S0BBAFAF
|
Humira | Adalimumab | Musculoskeletal and Joint Diseases | 1 |
|
Hyrimoz 40mg/0.8ml solution for injection pre-filled pens
1001030S0BEAAAB
|
Hyrimoz | Adalimumab | Musculoskeletal and Joint Diseases | 1 |
|
Imraldi 40mg/0.8ml solution for injection pre-filled pens
1001030S0BFAAAB
|
Imraldi | Adalimumab | Musculoskeletal and Joint Diseases | 1 |
|
Adalimumab 20mg/0.2ml inj pre-filled syringes
1001030S0AAAFAF
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 20mg/0.4ml inj pre-filled syringes
1001030S0AAAIAI
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 40mg/0.8ml inj pre-filled syringes
1001030S0AAAAAA
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 40mg/0.8ml solution for injection vials
1001030S0AAACAC
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 80mg/0.8ml inj pre-filled disposable devices
1001030S0AAAHAH
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 80mg/0.8ml inj pre-filled syringes
1001030S0AAAGAG
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita 20mg/0.4ml inj pre-filled syringes
1001030S0BCACAI
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita 40mg/0.8ml inj pre-filled syringes
1001030S0BCAAAA
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita 40mg/0.8ml solution for injection pre-filled pens
1001030S0BCABAB
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 20mg/0.2ml inj pre-filled syringes
1001030S0BCAHAF
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 40mg/0.4ml inj pre-filled syringes
1001030S0BCAGAE
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 80mg/0.8ml inj pre-filled pens
1001030S0BCADAH
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 80mg/0.8ml inj pre-filled syringes
1001030S0BCAEAG
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Hulio 40mg/0.8ml solution for injection pre-filled pens
1001030S0BDAAAB
|
Hulio | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Hulio 40mg/0.8ml solution for injection pre-filled syringes
1001030S0BDABAA
|
Hulio | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Humira 40mg/0.4ml solution for injection pre-filled syringes
1001030S0BBAEAE
|
Humira | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Humira 40mg/0.8ml solution for injection pre-filled pens
1001030S0BBABAB
|
Humira | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.